Comparative Pharmacology
Head-to-head clinical analysis: FLUMAZENIL versus ROMAZICON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLUMAZENIL versus ROMAZICON.
FLUMAZENIL vs ROMAZICON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist at GABA-A receptor benzodiazepine binding site, reversing CNS depression.
Competitive antagonist at the GABA-A receptor benzodiazepine binding site, reversing benzodiazepine effects.
Initial dose 0.2 mg IV over 15 seconds; if desired level of consciousness not achieved after 45 seconds, repeat 0.2 mg IV every 60 seconds up to a maximum total dose of 1 mg (usual cumulative dose 0.6-1 mg). For resedation, repeat doses at 20-minute intervals; maximum 3 mg/hour.
0.2 mg IV over 15 seconds, repeated at 1-minute intervals up to 1 mg; may repeat after 20 minutes if needed.
None Documented
None Documented
Terminal elimination half-life is 2.5-5 hours (mean ~3.5 h) in adults; prolonged to up to 25-30 hours in hepatic impairment; clinical context: single dose reverses benzodiazepine effects for 1-2 hours, but resedation may occur due to shorter half-life compared to long-acting benzodiazepines.
Clinical Note
moderateFlumazenil + Clozapine
"The risk or severity of adverse effects can be increased when Flumazenil is combined with Clozapine."
Clinical Note
moderateFlumazenil + Olanzapine
"The risk or severity of adverse effects can be increased when Flumazenil is combined with Olanzapine."
Clinical Note
moderateFlumazenil + Tasimelteon
"Flumazenil may decrease the sedative activities of Tasimelteon."
Clinical Note
moderateFlumazenil + Ramelteon
Terminal half-life 40-80 min; clinically repeated doses may be needed due to shorter duration than benzodiazepines
Primarily hepatic metabolism to inactive metabolites, with renal excretion of metabolites accounting for >90% of the dose; less than 1% unchanged drug excreted renally; fecal excretion negligible.
Renal: >90% as metabolites, <1% unchanged; biliary/fecal: minor
Category A/B
Category C
Benzodiazepine Antagonist
Benzodiazepine Antagonist
"Flumazenil may decrease the sedative activities of Ramelteon."